Table 2.
Age and tumor characteristics of patients in the American College of Surgeons Oncology Group Z0010 trial who had a negative SLN via H&E staining that was subsequently evaluated via IHC. (Data from: Giuliano AE, et al. Association of occult metastases in sentinel lymph nodes and bone marrow with survival among women with early-stage invasive breast cancer. JAMA 2011;306:385–93.)
| Variable | Negative via IHC (n=2977) | Positive via IHC (n=349) | P value |
|---|---|---|---|
|
| |||
| Age in years, median (range) | 57 (23–95) | 54 (27–87) | |
|
| |||
| Tumor size, cm | <.001 | ||
| ≤ 1.0 | 1260 (45%) | 101 (31%) | |
| 1.1 – 2.0 | 1202 (43%) | 161 (49%) | |
| > 2.0 | 330 (12%) | 67 (20%) | |
| Missing, number | 185 | 20 | |
|
| |||
| Histology | .002 | ||
| Ductal | 2387 (80%) | 262 (75%) | |
| Lobular | 226 (8%) | 45 (13%) | |
| Both | 77 (2%) | 14 (4%) | |
| Other | 284 (10%) | 28 (8%) | |
| Missing | 3 | 0 | |
|
| |||
| ER status | .3 | ||
| Positive | 2225 (81%) | 268 (84%) | |
| Negative | 518 (19%) | 53 (16%) | |
| Missing | 234 | 28 | |
|
| |||
| LVI | <.001 | ||
| Absent | 1921 (90%) | 217 (83%) | |
| Present | 205 (10%) | 44 (17%) | |
| Missing | 851 | 88 | |
IHC = immunohistochemistry
ER = estrogen receptor
LVI = lymphovascular invasion